The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss
Open accessThe DOI matches its Crossref record; 95 of the 95 references it cites were found in a registry or an index.
Abstract
Liraglutide is a glucagon-like peptide-1 (GLP-1) analog marketed for the treatment of type 2 diabetes. Besides lowering blood glucose, liraglutide also reduces body weight. It is not fully understood how liraglutide induces weight loss or to what degree liraglutide acts directly in the brain. Here, we determined that liraglutide does not activate GLP-1-producing neurons in the hindbrain, and liraglutide-dependent body weight reduction in rats was independent of GLP-1 receptors (GLP-1Rs) in the vagus nerve, area postrema, and paraventricular nucleus. Peripheral injection of fluorescently labeled liraglutide in mice revealed the presence of the drug in the circumventricular organs. Moreover, labeled liraglutide bound neurons within the arcuate nucleus (ARC) and other discrete sites in the hypothalamus. GLP-1R was necessary for liraglutide uptake in the brain, as liraglutide binding was not seen in Glp1r(-/-) mice. In the ARC, liraglutide was internalized in neurons expressing proopiomelanocortin (POMC) and cocaine- and amphetamine-regulated transcript (CART). Electrophysiological measurements of murine brain slices revealed that GLP-1 directly stimulates POMC/CART neurons and indirectly inhibits neurotransmission in neurons expressing neuropeptide Y (NPY) and agouti-related peptide (AgRP) via GABA-dependent signaling. Collectively, our findings indicate that the GLP-1R on POMC/CART-expressing ARC neurons likely mediates liraglutide-induced weight loss.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“GLP-1R and GIP-R have been identified in brain regions involved in the regulation of appetite, satiety, food/energy intake and energy expenditure, which is consistent with the significant impact on body weight observed with incretin therapy.”
From Adipose Tissue: A Novel Target of the Incretin Axis? A Paradigm Shift in Obesity-Linked Insulin Resistance (2024) · cites this paper as [29]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“These studies have demonstrated that the principal sites of action accessible to these drugs are GLP-1R neurons in circumventricular organs, particularly the AP and ME, and those in immediately adjacent regions—the NTS and arcuate nucleus of the hypothalamus (16, 51, 63‐66).”
From GLP-1 and the Neurobiology of Eating Control: Recent Advances (2025) · cites this paper as [51]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The individual necessity of distinct GLP-1R neuron populations for the anorectic and weight loss effects of GLP-1RAs has now been claimed by multiple studies using various loss-of-function approaches in rodents (47, 50‐54, 69).”
From GLP-1 and the Neurobiology of Eating Control: Recent Advances (2025) · cites this paper as [51]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Preclinical studies also indicate that tanycytes, specialized glial cells within the CNS, may facilitate the transportation of peripheral GLP-1RAs, such as semaglutide, into the CNS, bypassing the blood-brain barrier to access appetite-regulating hypothalamic regions such as the arcuate nucleus (60, 61).”
From The science of safety: adverse effects of GLP-1 receptor agonists as glucose-lowering and obesity medications (2026) · cites this paper as [61]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Recent mechanistic studies, primarily conducted in rodents, have identified a number of sites of direct action putatively mediating the effects of GLP-1-based AOMs on eating and body weight, including the area postrema and nucleus tractus solitarius (47‐49), locus coeruleus (50), hypothalamic arcuate (51, 52) and dorsomedial nuclei (53), and the lateral septal nucleus (54).”
From GLP-1 and the Neurobiology of Eating Control: Recent Advances (2025) · cites this paper as [51]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Central nervous system control of food intake
Schwartz, M. W., Woods, S. C., Porte, D., Seeley, R. J., & Baskin, D. G. (2000) · Nature · doi:10.1038/35007534 · Cited by 6,451 · cited 9×
“In 7 of 7 cells (from 5 mice), GLP-1(7-36)amide failed to change the current in the presence of bicuculline (Figure 2, D and F), demonstrating that GABA-A receptor activation was likely responsible for the inhibitory effects of GLP-1(7-36)amide on NPY neurons.”
InfluentialDrucker, D. J., & Nauck, M. A. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69705-5 · Cited by 3,896
The Physiology of Glucagon-like Peptide 1
Holst, J. J. (2007) · Physiological Reviews · doi:10.1152/physrev.00034.2006 · Cited by 3,371 · cited 2×
“Physiologically, GLP-1 released from endocrine cells lining the gut acts peripherally (13, 42).”
A role for glucagon-like peptide-1 in the central regulation of feeding
Turton, M. D., O'Shea, D., Gunn, I., Beak, S. A., Edwards, C. M. B., Meeran, K., Choi, S. J., Taylor, G. M., Heath, M. M., Lambert, P. D., et al. (1996) · Nature · doi:10.1038/379069a0 · Cited by 1,950 · cited 4×
“Given the well-known role of NTS-produced GLP-1 in appetite regulation, it is tempting to speculate that peripheral administration of GLP-1 or analogs activates NTS GLP-1–positive neurons that in turn reduce appetite (22, 23).”
InfluentialObesity is associated with hypothalamic injury in rodents and humans.
Thaler, J. P., Yi, C.-X., Schur, E. A., Guyenet, S. J., Hwang, B. H., Dietrich, M. O., Zhao, X., Sarruf, D. A., Izgur, V., Maravilla, K. R., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci59660 · Cited by 1,857
Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans.
Flint, A., Raben, A., Astrup, A., & Holst, J. J. (1998) · Journal of Clinical Investigation · doi:10.1172/jci990 · Cited by 1,402
GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus
Meier, J. J. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2012.140 · Cited by 1,311 · cited 1×
“…analogs, like exenatide and lixisenatide, display a marked reduction of GE, which may contribute to short-term effects on food intake, while liraglutide and exenatide, formulated for slow release, have only a minor effect on GE, which then cannot be the mediator of the body weight effects (16, 17).”
Hypothalamic CART is a new anorectic peptide regulated by leptin
Kristensen, P., Judge, M. E., Thim, L., Ribel, U., Christjansen, K. N., Wulff, B. S., Clausen, J. T., Jensen, P. B., Madsen, O. D., Vrang, N., et al. (1998) · Nature · doi:10.1038/29993 · Cited by 1,282 · cited 1×
“…access to the brain and how they may affect the key neuronal pathways that regulate energy balance, such as the neuropeptide Y/agouti-related peptide (NPY/ AgRP) and proopiomelanocortin/cocaine-and amphetamine-regulated transcript (POMC/CART) neurons located in the arcuate nucleus (ARC) (7–11).”
Self-citationAstrup, A., Rössner, S., Van Gaal, L., Rissanen, A., Niskanen, L., Al Hakim, M., Madsen, J., Rasmussen, M. F., & Lean, M. E. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61375-1 · Cited by 1,163 · cited 1×
“Liraglutide dose dependently lowers body weight by reducing energy intake via an overall appetite reduction (31, 32).”
NPY/AgRP Neurons Are Essential for Feeding in Adult Mice but Can Be Ablated in Neonates
Luquet, S., Perez, F. A., Hnasko, T. S., & Palmiter, R. D. (2005) · Science · doi:10.1126/science.1115524 · Cited by 1,125
Research works printed but not linked: 1
- Astrup A, Rossner S, Van Gaal L. Effects of lirag- lutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. Lancet. 2009;374(9701):1606-1616. · DOI · Paper page
Cited by
Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1
Drucker, D. J. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.03.001 · Cited by 2,170
“Moreover, a fluorescent liraglutide analog was detected within the ARC, PVN, supraoptic nucleus, and supraoptic decussation in both rats and mice after peripheral administration, with brain uptake dependent on a functional GLP-1R (Secher et al., GLP-1 levels rise following Roux-en-Y gastric bypass (RYGB) or after vert…”
BackgroundInfluentialGlucagon-like peptide 1 (GLP-1)
Müller, T. D., Finan, B., Bloom, S. R., D'Alessio, D., Drucker, D. J., Flatt, P. R., Fritsche, A., Gribble, F., Grill, H. J., Habener, J. F., et al. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.09.010 · Cited by 1,868
“While these studies suggest that GLP-1 influx into the brain might be a GLP-1R-independent process with passive diffusion of GLP-1 through the BBB [750e752], other studies suggest that uptake of liraglutide into the brain is GLP-1R-dependent [686,753].”
BackgroundInfluentialSelf-citationGLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art
Nauck, M. A., Quast, D. R., Wefers, J., & Meier, J. J. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101102 · Cited by 1,647
“POMC/CART neurons expressing GLP-1 receptors activate PB neurons and directly or indirectly suppress NPY/AgRP neurons [72,73], leading to disinhibition of suppressive signals to the PB (Figure 6).”
BackgroundObesity in adults: a clinical practice guideline
Wharton, S., Lau, D. C. W., Vallis, M., Sharma, A. M., Biertho, L., Campbell-Scherer, D., Adamo, K., Alberga, A., Bell, R., Boulé, N., et al. (2020) · Canadian Medical Association Journal · doi:10.1503/cmaj.191707 · Cited by 1,506
The Discovery and Development of Liraglutide and Semaglutide
Knudsen, L. B., & Lau, J. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00155 · Cited by 970
Self-citation
Metadata
- Authors
- Secher, A., Jelsing, J., Baquero, A. F., Hecksher-Sørensen, J., Cowley, M. A., Dalbøge, L. S., Hansen, G., Grove, K. L., Pyke, C., Raun, K., Schäffer, L., Tang-Christensen, M., Verma, S., Witgen, B. M., Vrang, N., & Bjerre Knudsen, L.
- Affiliations
- Novo Nordisk (Denmark) (DK)
- Gubra (Denmark) (DK)
- Oregon National Primate Research Center (US)
- Oregon Health & Science University (US)
- ORCID
- Venue
- Journal of Clinical Investigation
- Published
- 2014-09-09
- Volume
- 124
- Issue
- 10
- Pages
- 4473-4488
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC4215190
- OpenAlex
- W2014156217
- Cited by
- 961
- References
- 95
- Citations by year
- 2026: 100 · 2025: 126 · 2024: 123 · 2023: 85 · 2022: 77 · 2021: 93 · 2020: 56 · 2019: 63 · 2018: 62 · 2017: 65 · 2016: 52 · 2015: 53 · 2014: 5
- FWCI
- 28.44
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Novo Nordisk
- Topics
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Keywords
- liraglutide, GLP-1 receptor, arcuate nucleus, weight loss, hypothalamus, proopiomelanocortin neurons, neuropeptide Y, agouti-related protein, GABAergic inhibition, circumventricular organs, GLP-1 analogues, appetite regulation
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Liraglutide, Cocaine- and Amphetamine-Regulated Transcript Protein, Animals, Arcuate Nucleus of Hypothalamus, Body Weight, Disease Models, Animal, Electrophysiology, Hypothalamus, Male, Mice, Transgenic, Nerve Tissue Proteins, Neurons, Paraventricular Hypothalamic Nucleus, Pro-Opiomelanocortin, Vagus Nerve, Weight Loss, Rats, Sprague-Dawley, Receptors, Glucagon, Mice, Rats, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss. https://app.cochat.ai/papers/10.1172/jci75276
- The paper
- Secher, A., Jelsing, J., Baquero, A. F., Hecksher-Sørensen, J., Cowley, M. A., Dalbøge, L. S., Hansen, G., Grove, K. L., Pyke, C., Raun, K., Schäffer, L., Tang-Christensen, M., Verma, S., Witgen, B. M., Vrang, N., & Bjerre Knudsen, L. (2014). The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss. Journal of Clinical Investigation. https://doi.org/10.1172/jci75276
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.